Slides
Page 1
Q3 2026 E A R N I N G S P R E S E N T A T I O N November 3, 2026
Page 2
Chemours - Internal Use Only This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2026, the full year 2026 and the Company’s corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our to be filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law. We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position. Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP . This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com. Safe Harbor Statement and Other Matters 2
Page 3
Third Quarter 2026 Highlights Generated $1.5B in Net Sales and $200M in Adjusted EBITDA, supported by a ~10% increase in YoY TT pricing, paired with positive product mix shift in APM Completed the sale of the Kuan Yin property for total net consideration of ~$340 million, including the remaining land parcel for $56 million of gross proceeds Announced settlement with State of North Carolina and 11 local entities over Fayetteville Works discharges and unrelated PFAS claims, including AFFF use APM Performance Solutions net sales grew 26% YoY, underscoring momentum and mix shift towards high-value end markets for APM products Launched Chemours’ liquid cooling portfolio, including four two-phase direct- to-chip and one immersion cooling fluid under the Faizeon brand 3
Page 4
Chemours - Internal Use Only Third Quarter 2026 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 3Q26 3Q25 Y-o-Y ∆ 2Q26 Q-o-Q ∆ Net Sales $1,540 $1,495 $45 $1,591 ($51) Net (Loss) / Income1 $196 $46 $150 ($274) $470 Adj. Net Income 2 $31 $26 $5 $64 ($33) EPS 3 $1.29 $0.31 $0.98 ($1.81) $3.10 Adj. EPS 2,3 $0.21 $0.17 $0.04 $0.42 ($0.21) Adj. EBITDA 2,4 $200 $189 $11 $247 ($47) Operating Cash Flow $149 $146 $3 $158 ($9) Capex ($51) ($41) ($10) ($44) ($7) Free Cash Flow $98 $105 ($7) $114 ($16) FCF Conversion 49% 56% (7%) 46% 3% 4 1 Net (Loss) / Income attributable to The Chemours Company. 2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) IncomeAttributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. 3 Calculation based on diluted share count. 4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached “GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. .
Page 5
Chemours - Internal Use Only Adjusted EBITDA Bridge: 3Q26 versus 3Q25 $189 $200 $79 ($25) ($4)($39) 3Q25 Price Volume Cost/Other Currency 3Q26 ($ in millions) Price Impacts: $79 million due to higher pricing across the three primary segments, with strength in TiO2 pricing tied to the three disclosed pricing actions since December of 2025, paired with mix shift towards higher value Performance Solutions products within APM. Volume Impacts: ($25) million due to lower stationary AC aftermarket refrigerant sales of TSS Opteon blends in North America, compared with elevated demand in Q3 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act Cost/Other: ($39) million primarily driven by inflationary pressures experienced across the portfolio, partially offset by global net cost reduction efforts. Currency: ($4) million primarily driven by unfavorable currency dynamics within the APM and TSS business units. See reconciliation of Non-GAAP measures in the Appendix 5
Page 6
Chemours - Internal Use Only APM $354 $311 $337 3Q24 3Q25 3Q26 $139 $194 $136 3Q24 3Q25 3Q26 Quarterly Segment Summary ($ in millions unless otherwise noted) 30% 35% 27% Net Sales Adjusted EBITDA and Margin (%) $468 $560 $510 3Q24 3Q25 3Q26 TSS TSS 12% 4% 13% 11% 5% 7% TT $672 $612 $680 3Q24 3Q25 3Q26 TT $78 $25 $85 3Q24 3Q25 3Q26 APM $38 $14 $24 3Q24 3Q25 3Q26 6
Page 7
Chemours - Internal Use Only Liquidity Position as of September 30, 2026 ($ in millions unless otherwise noted) $3.9B $3.2B 4.3x Gross Debt TTM Net Leverage 10 Net Debt 9 $1.7BTotal Liquidity 8 5 Total cash balances include $103 million and $53 million of restricted cash and restricted cash equivalents on Chemours’ Balance Sheets as of September 30, 2026 and December 31, 2025, respectively. Restricted cash of $52 million at the end of thesecond quarter was related to the MOU Escrow and $103 million at the end of the third quarter reflected primarily the PFAS Insurance Escrow as will be further described in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 6 Operating cash flows for the third quarter of 2026 were $149 million, which includes the aforementioned receipt of $150 million in restricted cash related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by an approximate $100 million use of restricted cash to fund settlement payments associated with the 2025 settlement with the State of New Jersey and approximate $30 million of taxes related to the property sale in Kuan Yin. 7 Cash to shareholders reflects approximately $13 million in dividends paid to shareholders during the third quarter of 2026. 8 Total liquidity is calculated as the sum of $698 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030, and $220 million that expired on October 7, 2026. 9 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents. 10 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA. 7 $671 Unrestricted $698 Unrestricted $52 Restricted $149 ($51) ($13) ($7) $103 Restricted 2Q26 Cash Balance Operating Cash Flows Capex Cash to Shareholders Other 3Q26 Cash Balance $723 $801 5 576
Page 8
STRATEGIC PROGRESS PATHWAY TO THRIVE
Page 9
PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation To Create Shareholder Value Expanding Free Cash Flow Conversion & Long-Term Objective of Net Leverage Below 3x Across Economic Cycles Operational Excellence ❑Manufacturing excellence as a basis for success ❑Improved and standardized operating model for consistent execution ❑Continuous improvement to adapt to changing markets Strengthening the Long-Term ❑Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑Responsible manufacturing practices ❑Targeted policy efforts Enabling Growth ❑Investing smartly in selected growth projects ❑Commercial effectiveness to drive sales growth ❑Innovation and new product development Portfolio Management ❑Holistic portfolio analysis focused on distinct value creation metrics ❑Shift product mix to higher value applications in growing end markets ❑Optimize asset footprint >$250M cost reduction from 2024 to 2027 Recognizing criticality of our chemistriesDriving shareholder value >5% Sales CAGR from 2024 to 2027 9 Our Strategy
Page 10
Chemours - Internal Use Only Progress Achieved to Date PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation: Completed the sale of the Kuan Yin site for ~$340M of net consideration, positioning the Company to paydown €280M of outstanding debt, and helping to progress towards the long-term goal of below 3x net leverage Operational Excellence ✓ Notable progress against the $250M of run-rate savings by end of 2027 across all areas of the company ✓ Advanced the Chemours Business System rollout, embedding Lean principles to drive continuous improvement in safety, quality, and reliability ✓ Executed a long-term chlorine supply agreement with Olin Corporation, supporting the long-term competitiveness of the DeLisle TiO2 site Strengthening the Long-Term ✓ Announced settlement with State of North Carolina and 11 local entities over Fayetteville Works discharges and unrelated PFAS claims ✓ Reached a settlement with the EPA & WVDEP to resolve alleged permitting violations across three Chemours sites ✓ Settled with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Reduced fluorinated organic chemical (FOC) process emissions to air and water by 80% since 2018 ✓ Addressed $2B+ of near-term debt maturities in the past 12 months Enabling Growth ✓ Launched Chemours’ liquid cooling portfolio, including four two-phase direct-to-chip and one immersion cooling fluid under the Faizeon liquid cooling brand ✓ Continued sales in high-growth semiconductor and data center end markets approaching nearly half of APM Performance Solutions sales ✓ Realized approximately 10% of YoY pricing increase in TT in the third quarter of 2026 tied to previously announced pricing actions Portfolio Management ✓ Progressed APM European asset review, through the announced exit of the Villers-St. Paul site ✓ Exited SPS Capstone business to prioritize higher return businesses and strengthen Chemours’ overall portfolio ✓ Closed the sale of the former Kuan Yin TiO2 site in April 2026 ✓ Shifted aspects of TT’s mining operations to prioritize cash flow generation 10
Page 11
Chemours - Internal Use Only 11 Faizeon 100 Faizeon 110 Faizeon 200 Faizeon 220 Faizeon 500 Introducing: Retrofit deployments Lowest-pressure profile Thin cold-plate compatibility Low-pressure direct-to-chip Intermediate boiling point Strong material compatibility Performance / environmental balance Medium-pressure operation High-density AI and HPC Maximum thermal performance Advanced AI clusters High-density GPU environments Two-phase immersion cooling Extreme AI workloads Nonflammable, near-zero water use `
Page 12
Chemours - Internal Use Only ➢ Resolves litigations brought by the State of North Carolina ($75M) and 11 local entities ($380M) relating to PFAS and other historical discharges from Fayetteville Works, as well as the State’s claims of PFAS contamination unrelated to that site ($18M of the $455M settlement); Chemours’ $180M NPV obligation is covered by existing accruals ➢ For purposes of the MOU, all future settlements with payment overtime are to be considered over a 25-year period at a 8% discount rate and MOU escrow contributions by MOU parties are no longer required under the agreement NC Settlement Overview Strengthening the Long-Term: Resolving Legacy Liabilities Continued Progress 12 2017: 1st Ohio MDL Settlement ($670.7M) January 2021: MOU with Corteva, EID, DuPont and Chemours on PFAS Liabilities: Created $4B cost sharing arrangement 2nd Ohio MDL Settlement ($83M) February 2019: Consent Order with NCDEQ for Fayetteville Works July 2021: Delaware NRD Settlement ($50M + $25M supplement) June 2023: U.S. Public Water System Class Action Settlement ($1.185B) Reached Note: Finalized in Q2 2024 December 2024: 3rd Ohio MDL Settlement with Closure of MDL ($58.5M) November 2023: Ohio NRD Settlement Reached ($110M) Priorities for Resolving Remaining Legacy Matters Opt out water system claims that involve costs to abate or meet regulatory requirements Governmental-related claims, including regulatory agencies and State AGs (may arise in both regulatory process and litigation proceedings (state NRD matters)) Personal injury claims Property-related claims, primarily involving loss of value 1 2 3 4 July/August 2025: Hoosick Falls Settlement ($27M) NJ Settlement ($875M; ~$500M NPV) Insurance Proceeds MOU June 2026: Announced Settlement with EPA/WVDEP: $22.5M civil penalty and $90M for site-specific mitigation projects over 15 years September 2026: NC Settlement Announced with the state AG & 11 local entities ($455M; ~$360M NPV)
Page 13
FOURTH QUARTER GUIDANCE
Page 14
Fourth Quarter and Full Year 2026 Guidance Sequential Business Outlook: Consolidated o Net Sales: Expected to decrease in the (10%) to (5%) range sequentially o Adjusted EBITDA: Expected to range between $160 million and $185 million o Corporate Expenses: Expected to range between $40 million and $45 million o Capital Expenditures: Expected to range between $75 million and $85 million o Free Cash Flows: Reflecting a source of cash TSS o Net Sales: Expected to decrease in the low-twenties to high-teens percentage range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere. o Adjusted EBITDA: Expected to approximate $105 million to $115 million, primarily driven by the referenced seasonality. TT o Net Sales: Expected to decrease in the low-teens to high-single digits percentage range, driven by traditional coatings season seasonality in the North American architectural paints market. o Adjusted EBITDA: Expected to range between $60 million and $65 million, driven by the referenced seasonality and sales timing. APM o Net Sales: Expected to increase in the low-to-mid teens percentage range, driven by continued strength in the Performance Solutions order book. o Adjusted EBITDA: Expected to be between $40 million and $45 million, driven by the referenced order book strength. CapEx $220M - $230M Adjusted EBITDA $775M - $800M Net Sales Growth ~2% Full Year 2026 Outlook Free Cash Flow Conversion11 15%+ Fourth Quarter 2026 Outlook 14 11. Free Cash Flow Conversion includes receipt of $150 million related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by legal settlement payments in the year related to the finalization of the JCO with the State of New Jersey and the announced settlement with the State of North Carolina during the third quarter of 2026 as well as the taxes associated with the, now completed, Kuan Yin property sale.
Page 15
APPENDIX 15
Page 16
Chemours - Internal Use Only OpteonTM Refrigerants 66% OpteonTM Refrigerants 56% FreonTM Refrig. 17% ($2) $(48) FreonTM Refrig. 20% FP&O 17% FP&O 24% 3Q25 Price/Currency Volume 3Q26 16 TSS Segment Net Sales and Adjusted EBITDA (Unaudited) $194 $136 3Q25 Price/Currency Volume Cost/Other 3Q26 ($ in millions) % of total Net Sales ($ in millions) Net Sales: The 9% year-over-year decrease was driven by a 9% decrease in volumes and a slight decrease in price. The decrease in volumes was primarily attributable to lower North American stationary AC aftermarket sales of TSS Opteon blends compared with elevated demand in the prior-year quarter, which benefited from the initial aftermarket channel fill associated with the stationary AC technology transition under the U.S. AIM Act. Adjusted EBITDA: The decrease reflects the lower Opteon stationary aftermarket sales noted above and higher costs incurred during the period. 3Q26 % total refrigerants: Freon = 26% Opteon = 74% 3Q25 % total refrigerants: Freon = 20% Opteon = 80% $560 $510
Page 17
Chemours - Internal Use Only TiO2 97% TiO2 96% Minerals 3% $58 $9 Minerals 4% 3Q25 Price/Currency Volume 3Q26 17 TT Segment Net Sales and Adjusted EBITDA (Unaudited) $25 $85 3Q25 Price/Currency Volume Cost/Other 3Q26 ($ in millions) Net Sales: The increase was driven by a 10% increase in global pricing and a 1% increase in global volumes, partially offset by a slight currency headwind. Pricing increased across all regions in connection with recent pricing announcements, while global volume growth reflected strength in North America, Latin America, and APAC excluding China that more than offset lower volumes across EMEA and China. Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by the global pricing strength noted above and higher volumes, partially offset by inflationary cost pressures. ($ in millions) $612 $680
Page 18
Chemours - Internal Use Only $14 $24 3Q25 Price/Currency Volume Cost/Other 3Q26 Advanced Materials 61% Advanced Materials 55% Performance Solutions 39% $18 $8 Performance Solutions 45% 3Q25 Price/Currency Volume 3Q26 18 APM Segment Net Sales and Adjusted EBITDA (Unaudited) Net Sales: The 8% increase was primarily driven by a 6% increase in price and a 2% increase in volume, partially offset by a slight currency headwind. Performance Solutions Net Sales increased 26%, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets. Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by a favorable mix shift toward higher-value Performance Solutions products serving data center and semiconductor end markets, partially offset by higher costs incurred during the period. ($ in millions) % of total Net Sales ($ in millions) $311 $337
Page 19
Chemours - Internal Use Only 19 Segment Net Sales (Unaudited) 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by product group and segment OpteonTM refrigerants 200$ 227$ 205$ 178$ 279$ 375$ 368$ 243$ 313$ 337$ 287$ FreonTM refrigerants 173 173 146 124 97 123 98 113 162 150 100 Foam, propellants, and other 81 119 117 88 90 99 94 88 93 104 123 Total Thermal & Specialized Solutions 454 519 468 390 466 597 560 444 568 591 510 Titanium Dioxide 562 643 642 598 575 629 591 534 541 639 650 Minerals & Other 30 33 30 34 22 28 21 27 18 22 30 Total Titanium Technologies 592 676 672 632 597 657 612 561 559 661 680 Advanced materials 190 212 214 191 178 214 190 172 143 184 184 Performance solutions 113 133 140 133 116 132 121 141 100 142 153 Total Advanced Performance Materials 303 345 354 324 294 346 311 312 243 326 337 Performance chemicals and intermediates 14 13 14 13 11 15 12 12 11 13 13 Total Other Segment 14 13 14 13 11 15 12 12 11 13 13 Total net sales 1,363$ 1,553$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ 1,540$ 2024
Page 20
Chemours - Internal Use Only 20 Segment Net Sales by Region (Unaudited) 1 LATAM includes Mexico. 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by geographic region North America: Thermal & Specialized Solutions 271$ 308$ 256$ 194$ 233$ 336$ 316$ 241$ 326$ 340$ 268$ Titanium Technologies 246 274 270 236 267 282 252 221 235 267 282 Advanced Performance Materials 124 133 130 112 111 125 110 131 95 140 143 Other Segment 9 10 9 7 8 10 7 7 7 7 8 Total North America 650 725 665 549 619 753 685 599 663 754 701 Asia Pacific: Thermal & Specialized Solutions 39 53 55 53 53 59 69 53 71 72 70 Titanium Technologies 147 178 171 161 105 125 122 114 77 124 138 Advanced Performance Materials 105 127 138 148 115 147 138 132 89 117 133 Other Segment 3 2 3 3 2 3 3 3 2 4 3 Total Asia Pacific 294 360 367 365 275 334 332 301 239 317 344 Europe, the Middle East, and Africa: Thermal & Specialized Solutions 92 103 98 69 98 112 87 84 97 97 87 Titanium Technologies 124 130 126 131 142 156 141 128 151 156 138 Advanced Performance Materials 63 72 70 53 56 60 52 40 52 57 52 Other Segment 2 1 2 2 1 2 2 2 2 2 2 Total Europe, the Middle East, and Africa 281 306 296 255 297 330 282 254 302 312 279 Latin America (1): Thermal & Specialized Solutions 52 55 59 74 82 90 88 66 74 82 85 Titanium Technologies 74 95 105 104 83 94 97 99 96 114 122 Advanced Performance Materials 11 13 16 11 12 14 11 10 7 12 9 Other Segment — — — 1 — — — — — — — Total Latin America 137 163 180 190 177 198 196 175 177 208 216 Total net sales 1,362$ 1,554$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ 1,540$ 2024
Page 21
Chemours - Internal Use Only 21 Segment Net Sales & Adjusted EBITDA (Unaudited) 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Segment Net Sales Thermal & Specialized Solutions 454$ 519$ 468$ 390$ 466$ 597$ 560$ 444$ 568$ 591$ 510$ Titanium Technologies 592 676 672 632 597 657 612 561 559 661 680 Advanced Performance Materials 303 345 354 324 294 346 311 312 243 326 337 Other Non-Reportable Segment 14 13 14 13 11 15 12 12 11 13 13 Total Company Net Sales 1,363$ 1,553$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 1,329$ 1,381$ 1,591$ 1,540$ Segment Adjusted EBITDA Thermal & Specialized Solutions 150$ 160$ 139$ 122$ 141$ 207$ 194$ 128$ 190$ 213$ 136$ Titanium Technologies 69 83 78 70 50 47 25 23 18 48 85 Advanced Performance Materials 30 45 38 47 32 50 14 12 5 26 24 Other Non-Reportable Segment 2 3 3 - 1 4 2 1 3 2 1 Corporate Expenses (55) (77) (54) (69) (57) (47) (44) (34) (47) (42) (42) Segment Adjusted EBITDA Margin Thermal & Specialized Solutions 33% 31% 30% 31% 30% 35% 35% 29% 33% 36% 27% Titanium Technologies 12% 12% 12% 11% 8% 7% 4% 4% 3% 7% 13% Advanced Performance Materials 10% 13% 11% 15% 11% 14% 5% 4% 2% 8% 7% Other Non-Reportable Segment 14% 23% 21% 0% 9% 27% 17% 10% 27% 15% 8% 2024 2026
Page 22
Chemours - Internal Use Only 22 GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2) ($ in millions except per share amounts) Cash flows (used for) provided by operating activities $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts (Loss) income before income taxes 222$ 38$ (1)$ 132$ (290)$ Net (loss) income attributable to Chemours 196$ 1.29$ 46$ 0.31$ (274)$ (1.79)$ (154)$ (350)$ Non-operating pension and other post-retirement benefit income (2) (0.01) (4) (0.03) (3) (0.02) (10) (7) Exchange losses, net 4 0.03 1 0.01 1 0.01 8 11 Restructuring, asset-related, and other charges 3 0.02 4 0.03 3 0.02 23 61 Goodwill impairment charge — — — — — — — — Loss on extinguishment of debt 0 — — — 2 0.01 16 1 Gain on sales of assets and businesses, net (50) (0.33) (7) (0.05) (266) (1.74) (316) (8) Transaction costs — — — — — — 6 4 Qualified spend recovery (5) (0.03) (13) (0.09) (6) (0.04) (23) (39) Litigation-related (income) charges, net (138) (1) 8 0.05 225 1.47 126 301 Environmental charges 18 0.12 13 0.09 144 0.94 189 88 Adjustments made to income taxes — — (18) (0.12) 207 1.35 227 168 Provision for (benefit from) income taxes relating to reconciling items 5 0 (4) (0.03) 31 0.20 18 (80) Adjusted Net Income 31$ 0.21$ 26$ 0.17$ 64$ 0.42$ 110$ 150$ Net income attributable to non-controlling interests — — — (1) 1 Interest expense, net 69 68 68 274 268 Depreciation and amortization 79 80 80 319 311 All remaining provision for income taxes 21 15 35 42 52 Adjusted EBITDA 200$ 189$ 247$ 744$ 782$ Three Months Ended 2025 Three Months Ended September 30, 2026 June 30, 2025 Twelve Months Ended September 30, 2026 2025
Page 23
Chemours - Internal Use Only 23 GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2) ($ in millions except per share amounts) $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts Adjusted EBITDA 200$ 189$ 247$ 744$ 782$ Total debt principal 3,872$ 4,185$ Less: Cash and cash equivalents (698) (613) Total debt principal, net 3,174$ 3,572$ Net Leverage Ratio (calculated using GAAP earnings) 24x (12.3)x Net Leverage Ratio (calculated using Non-GAAP earnings) 4.3x 4.6x Weighted-average number of common shares outstanding - basic 151,330,846 150,320,265 151,225,044 Weighted-average number of common shares outstanding - diluted 151,909,595 150,781,614 152,813,557 Basic (loss) earnings per share of common stock (2) 1.29$ 0.31$ (1.81)$ Diluted (loss) earnings per share of common stock (1) (2) 1.29$ 0.31$ (1.81)$ Adjusted basic earnings per share of common stock (2) 0.21$ 0.17$ 0.42$ Adjusted diluted earnings per share of common stock (1) (2) 0.21$ 0.17$ 0.42$ September 30, June 30, September 30, Three Months Ended Three Months Ended Twelve Months Ended 2025 (1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended June 30, 2026. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended September 30, 2026 and 2025, and the three months ended June 30, 2026 as Adjusted Net Income was in a net income position. (2) Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers. * Note: $ per share columns may not sum due to rounding. 2026 2025 2025 2026
Page 24
Chemours - Internal Use Only 24 GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation (1) Cash flows provided by (used for) operating activities $ 149 $ 146 $ 158 $ 263 $ 127 Less: Purchases of property, plant, and equipment (51) (41) (44) (144) (168) Free Cash Flows $ 98 $ 105 $ 114 $ 119 $ (41) Adjusted EBITDA 200 189 247 616 614 Free Cash Flow Conversion 49% 56% 46% 19% (7)% Three Months Ended Nine Months Ended September 30, June 30, September 30, 2026 2025 2026 2026 2025 (1) Includes the receipt of $150 million related to the PFAS Insurance Proceeds MOU, in connection with the finalization of the JCO with the State of New Jersey, partially offset by approximately $100 million in related settlement payments in Q3 2026. See "Note 17 - Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements that will be included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details.
Page 25
Chemours - Internal Use Only 25 2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1) (2) Cash flows provided by operating activities $ 340 $ 390 Less: Purchases of property, plant, and equipment (220) (230) Free Cash Flows $ 120 $ 160 Adjusted EBITDA 775 800 Free Cash Flow Conversion 15% 20% (2) Includes the receipt of $150 million related to the PFAS Insurance Proceeds MOU, in connection w ith the finalization of the JCO w ith the State of New Jersey , partially offset by approx imately $100 million in related settlement pay ments in the y ear. Estimated Year Ended December 31, 2026 Low High (1) Cash flow s prov ided by operating activ ities is inclusiv e of the anticipated $30 million cash tax es associated w ith the sale of the Kuan Yin site.
Page 26
Chemours - Internal Use Only 26 2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1) Low High Net loss attributable to Chemours (100)$ (90)$ Restructuring, transaction, and other costs, net (2) 210 210 Adjusted Net Income 110 120 Interest expense, net 275 280 Depreciation and amortization 320 320 All remaining provision for income taxes 70 80 Adjusted EBITDA 775$ 800$ (Estimated) Year Ending December 31, 2026 (2) Restructuring, transaction, and other costs, net includes all reconciling items from net loss attributable to Chemours to Adjusted Net Income, including income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts. (1) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.
Page 27
® 2026 CHEMOURS. ALL RIGHTS RESERVED